Stifel Financial Corp Exact Sciences Corp Transaction History

Stifel Financial Corp

  • $93.7 Billion
  • Q4 2024

A detailed history of Stifel Financial Corp transactions in Exact Sciences Corp stock. As of the latest transaction made, Stifel Financial Corp holds 68,759 shares of EXAS stock, worth $3.48 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
68,759
Previous 80,961 15.07%
Holding current value
$3.48 Million
Previous $5.51 Million 29.92%
% of portfolio
0.0%
Previous 0.01%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 13, 2025
SELL
$49.33 - $71.97 $601,924 - $878,177
-12,202 Reduced 15.07%
68,759 $3.86 Million
Q3 2024

Nov 14, 2024
BUY
$42.43 - $70.83 $77,434 - $129,264
1,825 Added 2.31%
80,961 $5.51 Million
Q2 2024

Aug 13, 2024
SELL
$41.33 - $74.26 $510,260 - $916,813
-12,346 Reduced 13.5%
79,136 $3.34 Million
Q1 2024

May 13, 2024
SELL
$56.27 - $73.77 $47,097 - $61,745
-837 Reduced 0.91%
91,482 $6.32 Million
Q4 2023

Feb 12, 2024
BUY
$59.06 - $75.72 $1.92 Million - $2.46 Million
32,425 Added 54.14%
92,319 $6.83 Million
Q3 2023

Nov 13, 2023
BUY
$65.94 - $99.04 $300,818 - $451,820
4,562 Added 8.24%
59,894 $4.09 Million
Q2 2023

Aug 14, 2023
BUY
$62.68 - $95.05 $211,482 - $320,698
3,374 Added 6.49%
55,332 $5.2 Million
Q1 2023

May 12, 2023
SELL
$47.19 - $70.77 $135,860 - $203,746
-2,879 Reduced 5.25%
51,958 $3.52 Million
Q4 2022

Feb 13, 2023
SELL
$30.35 - $53.15 $136,605 - $239,228
-4,501 Reduced 7.59%
54,837 $2.71 Million
Q3 2022

Nov 14, 2022
BUY
$31.97 - $49.37 $62,597 - $96,666
1,958 Added 3.41%
59,338 $1.93 Million
Q2 2022

Aug 15, 2022
SELL
$35.61 - $76.23 $15,169 - $32,473
-426 Reduced 0.74%
57,380 $2.26 Million
Q1 2022

May 13, 2022
BUY
$57.56 - $82.54 $567,426 - $813,679
9,858 Added 20.56%
57,806 $4.04 Million
Q4 2021

Feb 14, 2022
SELL
$72.5 - $100.68 $370,982 - $515,179
-5,117 Reduced 9.64%
47,948 $3.73 Million
Q3 2021

Nov 15, 2021
SELL
$90.24 - $124.05 $4.78 Million - $6.58 Million
-53,020 Reduced 49.98%
53,065 $5.07 Million
Q2 2021

Aug 13, 2021
BUY
$93.66 - $139.27 $589,121 - $876,008
6,290 Added 6.3%
106,085 $13.2 Million
Q1 2021

May 14, 2021
BUY
$116.57 - $155.01 $574,107 - $763,424
4,925 Added 5.19%
99,795 $13.2 Million
Q4 2020

Feb 12, 2021
BUY
$99.61 - $142.12 $341,064 - $486,618
3,424 Added 3.74%
94,870 $12.6 Million
Q3 2020

Nov 16, 2020
SELL
$72.92 - $102.01 $882,113 - $1.23 Million
-12,097 Reduced 11.68%
91,446 $9.32 Million
Q2 2020

Aug 14, 2020
BUY
$55.75 - $92.75 $2.2 Million - $3.66 Million
39,449 Added 61.55%
103,543 $9 Million
Q1 2020

May 14, 2020
BUY
$37.9 - $104.44 $151,145 - $416,506
3,988 Added 6.63%
64,094 $3.72 Million
Q4 2019

Feb 13, 2020
BUY
$77.66 - $99.74 $1.59 Million - $2.04 Million
20,440 Added 51.53%
60,106 $5.54 Million
Q3 2019

Nov 13, 2019
BUY
$90.37 - $122.49 $670,816 - $909,243
7,423 Added 23.02%
39,666 $3.57 Million
Q2 2019

Aug 14, 2019
BUY
$89.51 - $118.04 $679,649 - $896,277
7,593 Added 30.8%
32,243 $3.81 Million
Q1 2019

May 14, 2019
BUY
$61.98 - $96.5 $139,269 - $216,835
2,247 Added 10.03%
24,650 $2.13 Million
Q4 2018

Feb 13, 2019
SELL
$56.04 - $82.66 $379,446 - $559,690
-6,771 Reduced 23.21%
22,403 $1.42 Million
Q3 2018

Nov 13, 2018
BUY
$48.29 - $80.6 $640,711 - $1.07 Million
13,268 Added 83.42%
29,174 $2.3 Million
Q2 2018

Aug 14, 2018
SELL
$37.84 - $69.96 $14,719 - $27,214
-389 Reduced 2.39%
15,906 $952,000
Q1 2018

May 11, 2018
SELL
$39.82 - $57.53 $45,434 - $65,641
-1,141 Reduced 6.54%
16,295 $656,000
Q4 2017

Feb 14, 2018
SELL
$46.49 - $60.51 $16,689 - $21,723
-359 Reduced 2.02%
17,436 $916,000
Q3 2017

Nov 13, 2017
BUY
$37.05 - $47.12 $659,304 - $838,500
17,795
17,795 $0

Others Institutions Holding EXAS

# of Institutions
665
Shares Held
156M
Call Options Held
2.38M
Put Options Held
2M
View Full List

About EXACT SCIENCES CORP

EXAS Quotes by TradingView
  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $8.95B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Stifel Financial Corp Portfolio

Follow Stifel Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Stifel Financial Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email